ROFERON-A SOLUTION 18 MILLION I.U./3ML 18 M / 3 ML
INTERFERON ALPHA-2A : 18 M / 3 ML · DIN 02217066 · HOFFMANN-LA ROCHE LIMITED
Health Canada status: CANCELLED POST MARKET
What is ROFERON-A SOLUTION 18 MILLION I.U./3ML?
ROFERON-A SOLUTION 18 MILLION I.U./3ML 18 M / 3 ML contains INTERFERON ALPHA-2A : 18 M / 3 ML. It is listed in the Health Canada Drug Product Database under DIN 02217066, held by HOFFMANN-LA ROCHE LIMITED, supplied as SOLUTION for SUBCUTANEOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 14-Jul-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ROFERON-A SOLUTION 18 MILLION I.U./3ML used for?
‘Roferon’-A (interferon alfa-2a) is indicated for use in the treatment of: Hairy Cell Leukemia, Kaposi's Sarcoma in patients with AIDS (Acquired Immune Deficiency Syndrome), Chronic Active Hepatitis B, Chronic Myelogeneous Leukemia (CML) and Thrombocytosis associated with CML, Renal Cell Carcinoma, Cutaneous T-Cell Lymphoma (CTCL), Chronic Hepatitis C.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02217066 |
|---|---|
| Brand name | ROFERON-A SOLUTION 18 MILLION I.U./3ML |
| Generic / active ingredient | INTERFERON ALPHA-2A : 18 M / 3 ML |
| Manufacturer | HOFFMANN-LA ROCHE LIMITED |
| Strength | 18 M / 3 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS ; INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | L03AB04 INTERFERON ALFA-2A |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 14-Jul-2005 |
How is it stored and handled?
Store in a refrigerator at 2 to 8°C. Protect from light. Do not freeze or shake. Multiple dose vials should be used within 30 days of the first withdrawal.
How is it supplied?
Vials containing 3 million IU interferon alfa-2a in 1 mL; Vials containing 9 million IU interferon alfa-2a in 1 mL; Vials (multiple dose) containing 9 million IU interferon alfa-2a in 0.9 mL; Vials (multiple dose) containing 18 million IU interferon alfa-2a in 3 mL; Vials containing 36 million IU interferon alfa-2a in 1 mL; 1 pre-filled syringe containing 3 million IU interferon alfa-2a in 0.5 mL plus 1 needle for s.c. injection; 1 pre-filled syringe containing 4.5 million IU interferon alfa-2a in 0.5 mL plus 1 needle for s.c. injection; 1 pre-filled syringe containing 6 million IU interferon alfa-2a in 0.5 mL plus 1 needle
What can be used instead?
Other Canadian products sharing ATC code L03AB04 INTERFERON ALFA-2A. 0 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ROFERON A SOLN INJ 6 MILLION | 6000000 UNIT | LIQUID | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 00812498 |
| ROFERON A STERILE PWS 18M UNIT/VIAL | 18000000 UNIT | POWDER FOR SOLUTION | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 01912003 |
| ROFERON A STERILE PWS 3M UNIT/VIAL | 3000000 UNIT | POWDER FOR SOLUTION | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 01911988 |
| ROFERON A STERILE PWS 9M UNIT/VIAL | 9000000 UNIT | POWDER FOR SOLUTION | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 01911996 |
| ROFERON-A SOL INJ 3MILLION IU/VIAL | 3000000 UNIT | LIQUID | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 00812501 |
| ROFERON-A SOLN-LIQ IM SC 4.5MILLION I.U/ML | 4.5 M | LIQUID | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 02217023 |
| ROFERON-A SOLN-LIQ IM SC 9MILLION I.U./ML | 9 M | SOLUTION | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 02217058 |
| ROFERON-A SOLUTION 3 MILLION I.U./ML | 3 M | SOLUTION | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 02217015 |
| ROFERON-A SOLUTION 6 MILLION I.U./ML | 6 M | SOLUTION | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 02217031 |
| ROFERON-A SOLUTION INJ 36000000UNIT/ML | 36000000 UNIT | SOLUTION | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 00891002 |
Who else supplies INTERFERON ALFA-2A worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INTERFERON ALFA-2A appears in 84 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.